Mesenchymal stem cell therapy (FCB-Pharmicell)

N/A

Report date: 2023/01/12 15:30:20

Base Information

Drug NameMesenchymal stem cell therapy (FCB-Pharmicell)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy
Mechanisms of ActionUpdating
TargetsNot applicable
Therapy Area/IndicationsAmyotrophic Lateral Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesFcb-Pharmicell
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesFcb-Pharmicell
Active IndicationsN/A
Inactive IndicationsAmyotrophic Lateral Sclerosis

Other Information

ATC CodeN/A
Related LinksN/A